Erika Yamada

Dr. Erika Yamada


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2025 in Cancers
Verified
Journal Article
Open access
PDF file
EYErika Yamada
Erika Yamada
EIEiichi Ishikawa
Eiichi Ishikawa
TMTSUBASA MIYAZAKI
TSUBASA MIYAZAKI
Hirofumi MatsuiHirofumi Matsui
Hirofumi Matsui
KAKazuki Akutagawa
Kazuki Akutagawa
HIHiroshi Ishikawa
Hiroshi Ishikawa
Background: This study explores the therapeutic potential of radiodynamic therapy (RDT), a combination of the photosensitizer 5-aminolevulinic acid (5-ALA) administration and X-ray irradiation, for high-grade glioma (HGG). The research aims to verify the RDT efficacy in both normoxic and hypoxic environments, examine its mechanisms, and assess its impact on the tumor micro-immune environment to address resistance to RDT. Methods: Glioma cell lines U87MG and U251MG were used in experiments in vitro. The cells were divided into four groups with or without 5-ALA and X-ray exposure. Results: Results demonstrated that RDT was effective under normoxia (20% O2), increasing reactive oxygen species (ROS) production and significantly decreasing U87MG cell viability in a 5-ALA concentration-dependent manner at 2 Gy and 6 Gy. However, under hypoxic conditions (3% O2) or long-term 3% O2 exposure, the RDT effect was not significant compared to controls. The study also found that RDT under normoxia influenced immune reaction-related gene expression, while under hypoxia, it primarily affects genes related to epithelial–mesenchymal transition (EMT). Further analysis revealed that RDT reduces the secretion of soluble PD-L1, a marker of immune checkpoint inhibition, in a 20% O2 environment. Additionally, RDT suppressed the vascular endothelial growth factor (VEGF), an angiogenesis marker, under 3% O2 conditions. RDT also reduced the secretion of colony-stimulating factor -1 (CSF-1), a differentiation inhibitory marker for macrophages, in a 20% O2 environment. Conclusion: In conclusion, this study provides evidence that RDT, combining 5-ALA and X-ray irradiation, has potential as a therapeutic strategy for HGG, especially under normoxic conditions. It may also offer benefits under hypoxia, particularly in inhibiting angiogenesis. The study also highlights the importance of understanding the role of oxygen levels in the efficacy of RDT and its potential impact on immune responses, angiogenesis, and macrophage differentiation in the tumor microenvironment. Further research is needed to fully elucidate the underlying mechanisms and optimize RDT for clinical application.

12 June 2025 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
KAKazuki Akutagawa
Kazuki Akutagawa
SMShunichiro Miki
Shunichiro Miki
EYErika Yamada
Erika Yamada
NSNoriaki Sakamoto
Noriaki Sakamoto
TMTSUBASA MIYAZAKI
TSUBASA MIYAZAKI
EIEiichi Ishikawa
Eiichi Ishikawa
Background: Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, characterized by high invasiveness and a poor prognosis, with limited treatment options. Our previous study on fractionated radiotherapy, temozolomide, and an autologous formalin-fixed tumor vaccine (AFTV) for newly diagnosed grade 4 astrocytic tumors demonstrated that complete tumor resection and p53 negativity on immunohistochemistry were associated with favorable outcomes. PIK3R2, a key component of the PI3K–Akt signaling pathway, may modulate the host immune response to tumor antigens and influence the efficacy of immunotherapy. In this study, we further investigated whether PIK3R2, a candidate gene identified through gene panel sequencing as potentially associated with prognosis following AFTV treatment, influences patient outcomes after AFTV therapy. Methods: We analyzed 58 patients with newly diagnosed IDH wildtype GBM or IDH mutant grade 4 astrocytoma (Astro). Among them, 29 received standard treatment combined with AFTV (AFTV group), while 29 underwent standard treatment alone (control group). Immunostaining for PIK3R2 and p53 was performed, and patient characteristics, including age, sex, Karnofsky Performance Status at the time of surgery, and overall survival (OS), were evaluated. PIK3R2 expression levels were classified using a 34% cutoff value. Results: In the AFTV group, survival analysis based on PIK3R2 status (positive/negative) revealed an increased survival in the PIK3R2-negative group when comparing AFTV and control groups (p = 0.075 in GBM/Astro cases and p = 0.030 in GBM cases). When stratifying patients into four subgroups based on p53 and PIK3R2 status (p53-negative/PIK3R2-negative, p53-positive/PIK3R2-positive, p53-negative/PIK3R2-positive, and p53-positive/PIK3R2-negative), a significant improvement in OS was observed in the p53-negative/PIK3R2-negative group both in GBM/Astro cases and GBM cases. PD-1 demonstrated the strongest correlation with PIK3R2 in the regression analysis. Conclusion: Negative immunostaining for PIK3R2 as well as negative p53 revealed an increased survival in patients receiving AFTV therapy for GBM. In patients receiving AFTV, these immunostaining results may serve as a predictor of treatment efficacy and overall survival.

1 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
EYErika Yamada
Erika Yamada
EIEiichi Ishikawa
Eiichi Ishikawa
TMTSUBASA MIYAZAKI
TSUBASA MIYAZAKI
Hirofumi MatsuiHirofumi Matsui
Hirofumi Matsui
KAKazuki Akutagawa
Kazuki Akutagawa
HIHiroshi Ishikawa
Hiroshi Ishikawa
Background: This study explores the therapeutic potential of radiodynamic therapy (RDT), a combination of the photosensitizer 5-aminolevulinic acid (5-ALA) administration and X-ray irradiation, for high-grade glioma (HGG). The research aims to verify the RDT efficacy in both normoxic and hypoxic environments, examine its mechanisms, and assess its impact on the tumor micro-immune environment to address resistance to RDT. Methods: Glioma cell lines U87MG and U251MG were used in experiments in vitro. The cells were divided into four groups with or without 5-ALA and X-ray exposure. Results: Results demonstrated that RDT was effective under normoxia (20% O2), increasing reactive oxygen species (ROS) production and significantly decreasing U87MG cell viability in a 5-ALA concentration-dependent manner at 2Gy and 6Gy. However, under hypoxic conditions (3% O2) or long-term 3% O2 exposure, the RDT effect was not significant compared to controls. The study also found that RDT under normoxia influenced immune reaction-related gene expression, while under hypoxia, it primarily affects genes related to epithelial-mesenchymal transition (EMT). Further analysis revealed that RDT reduces the secretion of soluble PD-L1, a marker of immune checkpoint inhibition, in a 20% O2 environment. Additionally, RDT suppressed the vascular endothelial growth factor (VEGF), an angiogenesis marker, under 3% O2 conditions. RDT also reduced the secretion of colony-stimulating factor -1 (CSF-1), a differentiation inhibitory marker for macrophages, in a 20% O2 environment. Conclusion: In conclusion, this study provides evidence that RDT, combining 5-ALA and X-ray irradiation, has potential as a therapeutic strategy for HGG, especially under normoxic conditions. It may also offer benefits under hypoxia, particularly in inhibiting angiogenesis. The study also highlights the importance of understanding the role of oxygen levels in the efficacy of RDT and its potential impact on immune responses, angiogenesis, and macrophage differentiation in the tumor microenvironment. Further research is needed to fully elucidate the underlying mechanisms and optimize RDT for clinical application.